2. Immunology/Inflammation
  3. CD74
  4. Milatuzumab

Milatuzumab  (Synonyms: hLL1; MEDI-115)

製品番号: HY-P99731 純度: 99.39%
COA Technical Support

Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 899796-83-9

容量 価格（税別） 在庫状況 数量
>無料サンプル (100 μg)   今すぐ申し込む  
1 mg $280 在庫あり
5 mg $910 在庫あり
10 mg $1450 在庫あり
25 mg $2900 在庫あり
50 mg   お問い合わせ  
100 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 4 publication(s) in Google Scholar

Milatuzumab Featured Recommendations:

Milatuzumab 関連抗体

Top Publications Citing Use of Products

    Milatuzumab purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jun 23:e02838.  [Abstract]

    HCAEC cells were treated with ox-LDL and anti-CD74 antibody (Milatuzumab: 15 mg/kg) for 12 hours, stained with 1 µg/ml WGA-Alexa 488 and CD80, and observed under a confocal microscope.

    Milatuzumab purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jun 23:e02838.  [Abstract]

    Western blot analysis of migratory bodies and M1 macrophage-related markers in HCAEC cells treated with ox-LDL and anti-CD74 antibody (Milatuzumab: 15 mg/kg) was performed.

    Milatuzumab purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jun 23:e02838.  [Abstract]

    Immunofluorescence images showing M1 macrophages and migrasomes in Control, AS, and AS_Anti CD74 (Milatuzumab: 15 mg/kg) groups. Red: WGA‐594 (labeling migrasomes); Green: iNOS (labeling M1 macrophages); Magenta: CD206 (labeling M2 macrophages); Blue: DAPI (nuclei).

    Milatuzumab purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Aug 6;12(8):e009024.  [Abstract]

    Macrophages derived from THP-1 cells treated with anti-CD74 (Milatuzumab) were co-cultured. Phagocytic efficiency was quantified as the percentage of dual-fluorescence-positive macrophages (upper right quadrant).

    Milatuzumab purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Aug 6;12(8):e009024.  [Abstract]

    Flow cytometry was used to detect differences in phagocytic function among the control group, cisplatin group, and combination therapy group with anti-CD74 Ab (5 µg/mL). THP-1-derived macrophages were co-cultured with SiHa cells.

    • 生物活性

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー

    製品説明

    Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death[1].

    Isotype

    Human IgG1 kappa
    Recommend Isotype Controls
    Species Reactivity

    Human
    IC50 & Target

    CD74
    体外実験

    Milatuzumaba (5 μg/mL; 8-48 h) enhances cell death in MCL cell lines and primary patient tumor cells[1].
    Milatuzumaba (5 μg/mL; 0.5-2 h) mediates the cytotoxicity partially depending on generation of ROS and loss of mitochondrial transmembrane potential in Jeko, Mino, and SP-53 cells[1].
    Milatuzumaba (5 μg/mL; 4 h) inhibits NF-κB pathway and induces cell apoptosis with independent of caspase cleavage, Bcl-2 family member dysregulation, or induction of autophagy[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Milatuzumab 関連抗体

    Western Blot Analysis[1]

    Cell Line: Jeko and Mino cells
    Concentration: 5 μg/mL
    Incubation Time: 4 hours
    Result: Insignificant down-regulation of antiapoptotic proteins, such as Bax, Bcl-2, Bcl-xL, and Mcl-1.

    Cell Viability Assay[1]

    Cell Line: MCL cell lines and primarypatient tumor cells
    Concentration: 5 μg/mL
    Incubation Time: 8, 24, and 48 hours
    Result: Resulted in cell death of Jeko, Mino, SP-53, Rec-1, HBL-2, and Granta cells.

    Immunofluorescence[1]

    Cell Line: Jeko, Mino, and SP-53 cells
    Concentration: 5 μg/mL; with or without 10 mM N-acetylcysteine (HY-B0215) for 1.5 h
    Incubation Time: 0.5, 1, 1.5, and 2 hours
    Result: Increased ROS generation as early as 0.5 hours, while peaking at 1 to 1.5 hours and reducing at 2 hours.Therefore, it resulted cell death, but reserved by nonspecific ROS scavenger.
    体内実験

    Milatuzumaba (15 mg/kg/day; i.p.; once every 3 days) significantly increases the survival rate of female SCID mice bearing Jeko cells. And Milatuzumaba has a synergistic effect with Rituximab (HY-P9913) in mouse model[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Jeko mouse model[1]
    Dosage: 15 mg/kg/day; with or without 15 mg/kg Rituximab
    Administration: Intraperitoneal injection; once every 3 days, starting at day 15 after engraftment
    Result: Resulted the mean survival for the combination treated group of 44.5 days, compared with 33.5 days for Milatuzumaba treated, 28 days for control.
    臨床実験
    Gene ID

    972  [NCBI]

    Accession
    Application

    ELISA, FACS, Functional assay
    Conjugated

    Unconjugated
    Reconsititution

    The product can be reconstituted/diluted with sterile PBS or saline.
    分子量

    145.66 kDa

    CAS 番号
    Appearance

    Liquid

    Color

    Colorless to light yellow

    SMILES

    [Milatuzumab]
    輸送条件

    Shipping with dry ice.
    Formulation

    Please refer to the lot-specific COA for specific buffer information.
    保管条件

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Format
    • Human IgG1 kappa
    Biological Activity
    • Immobilized hu-CD74-ECD-His can bind Milatuzumab. The EC50 for this effect is 3.941 ng/mL.
    • Flow Cytometry analysis of Raji cells labelling CD74 (red) with Milatuzumab (anti-CD74) (HY-P99731). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
    純度とドキュメンテーション

    純度: 99.39%

    COA (232 KB)

    Inhibitory Antibodies User Guide (603 KB)
    参考文献
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Milatuzumab Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量   濃度   体積   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Milatuzumab899796-83-9hLL1 MEDI-115hLL 1hLL-1MEDI115MEDI 115MEDI-115CD74HLA-DR-gammaInvariant polypeptide of major histocompatibility complex, class II antigen-associatedInhibitorinhibitorinhibit

    最近チェックした製品:

    オンラインお問い合わせ

    Your information is safe with us. * Required Fields.

    製品名

    		  

    カスタマ需要量 *

    お名前 *

    		 

    タイトル

    メールアドレス *

    		 

    電話番号 *

    デパートメント

    		 

    組纖名 *

    市区町村

    都道府県

    国或いは地域 *

    		      

    必ず会社名を記載ください。個人への返信は行いません。

    備考

    バルクお問い合わせ

    Inquiry Information

    製品名:
    Milatuzumab
    製品番号:
    HY-P99731
    数量:
    MCE 日本正規代理店:

    カスタマーレビュー

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    製品名

    		  

    Lot #

    お名前 *

    		 

    メールアドレス *

    電話番号 *

    		 

    部門 *

    組纖名 *

    		 

    国或いは地域 *

    備考

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.